Oxford Biomedica plc (OXB.L)
LSE · GBp · Healthcare · Biotechnology
£530.80 (+0.72%) as of
Key statistics
- Market cap
- 642.55M
- Forward P/E
- -72.59
- EPS (TTM)
- -0.32
- Dividend yield
- 0.00%
- 52-week range
- 420.00 – 962.00
- Beta
- 1.11
- Revenue (TTM)
- 175.36M
- Profit margin
- -23.23%
- Analyst target
- £703.50
- Volume
- 43.65k
About Oxford Biomedica plc
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oxford, United Kingdom
- Employees
- 1,017
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.